Aeterna Zentaris (AEZS) +7.6%, with the main news being the publication of an article describing...

|By:, SA News Editor

Aeterna Zentaris (AEZS) +7.6%, with the main news being the publication of an article describing how the firm's perifosine compound could be used to treat Malignant Pleural Mesothelioma, an aggressive cancer associated with exposure to asbestos. Shares were hit in April after the failure of a Phase III trial for colorectal cancer. (PR)